{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:11:06Z","timestamp":1790806266869,"version":"4.1.0"},"reference-count":253,"publisher":"Elsevier","isbn-type":[{"value":"9780128183618","type":"print"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/bs.pmbts.2019.05.001","type":"book-chapter","created":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T07:35:02Z","timestamp":1559979302000},"page":"63-106","source":"Crossref","is-referenced-by-count":17,"title":["AD molecular: PET amyloid imaging across the Alzheimer's disease spectrum: From disease mechanisms to prevention"],"prefix":"10.1016","author":[{"given":"Pierre-Fran\u00e7ois","family":"Meyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"McSweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Gonneaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Villeneuve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.pmbts.2019.05.001_bb0010","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer's disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0015","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1212\/WNL.38.11.1682","article-title":"Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease","volume":"38","author":"Crystal","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0020","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/ana.410230206","article-title":"Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques","volume":"23","author":"Katzman","year":"1988","journal-title":"Ann Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0025","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/0006-291X(84)91209-9","article-title":"Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein","volume":"122","author":"Glenner","year":"1984","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0030","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","article-title":"Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein","volume":"120","author":"Glenner","year":"1984","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0035","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3233\/JAD-2010-1221","article-title":"Alzheimer's disease and the amyloid-beta peptide","volume":"19","author":"Murphy","year":"2010","journal-title":"J Alzheimer's Dis"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0040","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1126\/science.8191290","article-title":"An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants","volume":"264","author":"Suzuki","year":"1994","journal-title":"Science"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0045","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1073\/pnas.222681699","article-title":"Amyloid beta-protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways","volume":"100","author":"Bitan","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0050","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1152\/physrev.2001.81.2.741","article-title":"Alzheimer's disease: genes, proteins, and therapy","volume":"81","author":"Selkoe","year":"2001","journal-title":"Physiol Rev"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0055","doi-asserted-by":"crossref","first-page":"8876","DOI":"10.1523\/JNEUROSCI.19-20-08876.1999","article-title":"Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons","volume":"19","author":"Hartley","year":"1999","journal-title":"J Neurosci"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0060","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1523\/JNEUROSCI.20-11-04050.2000","article-title":"High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation","volume":"20","author":"Mucke","year":"2000","journal-title":"J Neurosci"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0065","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0166-2236(00)01749-5","article-title":"Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?","volume":"24","author":"Klein","year":"2001","journal-title":"Trends Neurosci"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0070","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2019.0834","article-title":"Association of cortical beta-amyloid protein in the absence of insoluble deposits with Alzheimer disease","author":"Yu","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0075","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cpet.2009.12.008","article-title":"Amyloid PET ligands for dementia","volume":"5","author":"Villemagne","year":"2010","journal-title":"PET Clin"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0080","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00019442-200201000-00004","article-title":"Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease","volume":"10","author":"Shoghi-Jadid","year":"2002","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0085","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0090","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/brain\/awn016","article-title":"Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease","volume":"131","author":"Ikonomovic","year":"2008","journal-title":"Brain"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb9000","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/B978-0-12-394816-8.00002-7","article-title":"Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta","volume":"64","author":"Cohen","year":"2012","journal-title":"Adv Pharmacol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0095","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1053\/j.semnuclmed.2011.03.001","article-title":"Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent","volume":"41","author":"Lister-James","year":"2011","journal-title":"Semin Nucl Med"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0100","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.nucmedbio.2012.03.001","article-title":"In vitro characterization of [18F]-florbetaben, an Abeta imaging radiotracer","volume":"39","author":"Fodero-Tavoletti","year":"2012","journal-title":"Nucl Med Biol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0110","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bmcl.2008.12.069","article-title":"Synthesis of 18F-labelled 2-(4'-fluorophenyl)-1,3-benzothiazole and evaluation as amyloid imaging agent in comparison with [11C]PIB","volume":"19","author":"Serdons","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0115","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrneurol.2018.9","article-title":"Imaging tau and amyloid-beta proteinopathies in Alzheimer disease and other conditions","volume":"14","author":"Villemagne","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0120","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2010.2008","article-title":"Use of florbetapir-PET for imaging beta-amyloid pathology","volume":"305","author":"Clark","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0125","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","article-title":"Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study","volume":"11","author":"Clark","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0130","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1474-4422(11)70077-1","article-title":"Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study","volume":"10","author":"Barthel","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0135","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","article-title":"Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study","volume":"11","author":"Sabri","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0140","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaneurol.2014.4144","article-title":"Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density","volume":"72","author":"Curtis","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0145","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s00259-009-1182-1","article-title":"Detection of amyloid in Alzheimer's disease with positron emission tomography using [11C]AZD2184","volume":"36","author":"Nyberg","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0150","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/359325a0","article-title":"Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids","volume":"359","author":"Seubert","year":"1992","journal-title":"Nature"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0155","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ana.410380413","article-title":"Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease","volume":"38","author":"Motter","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0160","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1212\/01.WNL.0000046581.81650.D0","article-title":"CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study","volume":"60","author":"Strozyk","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0165","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/brain\/awu367","article-title":"Independent information from cerebrospinal fluid amyloid-beta and florbetapir imaging in Alzheimer's disease","volume":"138","author":"Mattsson","year":"2015","journal-title":"Brain"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0170","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/brain\/aww015","article-title":"Alzheimer's disease neuroimaging I. Cerebrospinal fluid analysis detects cerebral amyloid-beta accumulation earlier than positron emission tomography","volume":"139","author":"Palmqvist","year":"2016","journal-title":"Brain"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0175","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/s41467-017-01150-x","article-title":"Earliest accumulation of beta-amyloid occurs within the default-mode network and concurrently affects brain connectivity","volume":"8","author":"Palmqvist","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0180","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/ana.23908","article-title":"Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloid","volume":"74","author":"Landau","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0185","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s00259-015-3228-x","article-title":"Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis","volume":"43","author":"Morris","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0190","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1602\/neurorx.1.2.213","article-title":"Cerebrospinal fluid protein biomarkers for Alzheimer's disease","volume":"1","author":"Blennow","year":"2004","journal-title":"NeuroRx"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0195","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-beta biomarkers for Alzheimer's disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0200","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.nicl.2013.02.006","article-title":"Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease","volume":"2","author":"Chetelat","year":"2013","journal-title":"Neuroimage Clin"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0205","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ana.22068","article-title":"18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial","volume":"68","author":"Vandenberghe","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0210","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00259-012-2088-x","article-title":"Comparison of 11C-PiB and 18F-florbetaben for Abeta imaging in ageing and Alzheimer's disease","volume":"39","author":"Villemagne","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0215","series-title":"Basic PET Data Analysis Techniques. Positron Emission Tomography-Recent Developments in Instrumentation, Research and Clinical Oncological Practice","author":"Yoder","year":"2013"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0220","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.arr.2016.01.005","article-title":"Amyloid imaging: past, present and future perspectives","volume":"30","author":"Villemagne","year":"2016","journal-title":"Ageing Res Rev"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0225","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2967\/jnumed.114.148981","article-title":"Measurement of longitudinal beta-amyloid change with 18F-florbetapir PET and standardized uptake value ratios","volume":"56","author":"Landau","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0230","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2967\/jnumed.114.149732","article-title":"Improved power for characterizing longitudinal amyloid-beta PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region","volume":"56","author":"Chen","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0235","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13195-016-0172-3","article-title":"Reference tissue normalization in longitudinal (18)F-florbetapir positron emission tomography of late mild cognitive impairment","volume":"8","author":"Shokouhi","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0240","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.neuroimage.2016.08.056","article-title":"Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE","volume":"144","author":"Schwarz","year":"2017","journal-title":"Neuroimage"},{"issue":"suppl 1","key":"10.1016\/bs.pmbts.2019.05.001_bb0245","doi-asserted-by":"crossref","first-page":"S159","DOI":"10.1016\/j.neurobiolaging.2014.04.033","article-title":"Comparison of MR-less PiB SUVR quantification methods","volume":"36","author":"Bourgeat","year":"2015","journal-title":"Neurobiol Aging"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0250","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1002\/hbm.23622","article-title":"Contributions of imprecision in PET-MRI rigid registration to imprecision in amyloid PET SUVR measurements","volume":"38","author":"Schwarz","year":"2017","journal-title":"Hum Brain Mapp"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid project: standardizing quantitative amyloid plaque estimation by PET","volume":"11","author":"Klunk","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0260","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.2967\/jnumed.115.171595","article-title":"Standardized expression of 18F-NAV4694 and 11C-PiB beta-amyloid PET results with the Centiloid scale","volume":"57","author":"Rowe","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0265","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.jalz.2018.06.1353","article-title":"Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale","volume":"14","author":"Navitsky","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0270","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1007\/s00259-017-3749-6","article-title":"(18)F-Florbetaben PET beta-amyloid binding expressed in Centiloids","volume":"44","author":"Rowe","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0275","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.neuroimage.2018.08.044","article-title":"Implementing the Centiloid transformation for (11)C-PiB and beta-amyloid (18)F-PET tracers using CapAIBL","volume":"183","author":"Bourgeat","year":"2018","journal-title":"Neuroimage"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0280","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","article-title":"Multisite study of the relationships between antemortem [(11)C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology","volume":"15","author":"La Joie","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0285","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13195-019-0478-z","article-title":"Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers","volume":"11","author":"Salvado","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb9005","first-page":"332","article-title":"The use of centiloids for applying [(11)C]PiB classification cutoffs across region-of-interest delineation methods","volume":"10","author":"Tudorascu","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0290","first-page":"180","article-title":"Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies","volume":"11","author":"Su","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0295","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0b013e3182840bbe","article-title":"Brain beta-amyloid load approaches a plateau","volume":"80","author":"Jack","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0300","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006171","article-title":"The neuropsychological profile of Alzheimer disease","volume":"2","author":"Weintraub","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0305","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev.psych.57.102904.190024","article-title":"Neuropsychological assessment of dementia","volume":"60","author":"Salmon","year":"2009","journal-title":"Annu Rev Psychol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0310","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(04)00710-0","article-title":"Amnestic MCI or prodromal Alzheimer's disease?","volume":"3","author":"Dubois","year":"2004","journal-title":"Lancet Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0315","first-page":"155","article-title":"Disorders of memory in Alzheimer's disease","volume":"vol 2","author":"Salmon","year":"2000"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0320","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1212\/WNL.42.3.631","article-title":"Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease","volume":"42","author":"Arriagada","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0325","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1093\/brain\/awl178","article-title":"Two-year follow-up of amyloid deposition in patients with Alzheimer's disease","volume":"129","author":"Engler","year":"2006","journal-title":"Brain"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0330","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/brain\/awp062","article-title":"Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease","volume":"132","author":"Jack","year":"2009","journal-title":"Brain"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0335","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1212\/01.wnl.0000261919.22630.ea","article-title":"Imaging beta-amyloid burden in aging and dementia","volume":"68","author":"Rowe","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0340","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.neurobiolaging.2010.03.011","article-title":"Cognition, glucose metabolism and amyloid burden in Alzheimer's disease","volume":"33","author":"Furst","year":"2012","journal-title":"Neurobiol Aging"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0345","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jamaneurol.2018.0629","article-title":"Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population-based setting","volume":"75","author":"Roberts","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0350","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1093\/brain\/aws125","article-title":"Regional dynamics of amyloid-beta deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study","volume":"135","author":"Villain","year":"2012","journal-title":"Brain"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0355","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41583-018-0067-3","article-title":"Imaging the evolution and pathophysiology of Alzheimer disease","volume":"19","author":"Jagust","year":"2018","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0360","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/brain\/aws327","article-title":"Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease","volume":"136","author":"Lehmann","year":"2013","journal-title":"Brain"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0365","doi-asserted-by":"crossref","first-page":"16265","DOI":"10.1523\/JNEUROSCI.2170-12.2012","article-title":"Region-specific hierarchy between atrophy, hypometabolism, and beta-amyloid (Abeta) load in Alzheimer's disease dementia","volume":"32","author":"La Joie","year":"2012","journal-title":"J Neurosci"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0370","doi-asserted-by":"crossref","first-page":"7709","DOI":"10.1523\/JNEUROSCI.2177-05.2005","article-title":"Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory","volume":"25","author":"Buckner","year":"2005","journal-title":"J Neurosci"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0375","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/brain\/awv112","article-title":"Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation","volume":"138","author":"Villeneuve","year":"2015","journal-title":"Brain"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0380","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1212\/WNL.0000000000004733","article-title":"Increased florbetapir binding in the temporal neocortex from age 20 to 60 years","volume":"89","author":"Gonneaud","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0385","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.tics.2005.07.001","article-title":"Parietal lobe contributions to episodic memory retrieval","volume":"9","author":"Wagner","year":"2005","journal-title":"Trends Cogn Sci"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0390","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/brain\/awv338","article-title":"Cascading network failure across the Alzheimer's disease spectrum","volume":"139","author":"Jones","year":"2016","journal-title":"Brain"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0395","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3389\/fnagi.2015.00042","article-title":"Are AD-typical regions the convergence point of multiple pathologies?","volume":"7","author":"Villeneuve","year":"2015","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0400","doi-asserted-by":"crossref","first-page":"7364","DOI":"10.1523\/JNEUROSCI.0639-16.2016","article-title":"In vivo tau, amyloid, and gray matter profiles in the aging brain","volume":"36","author":"Sepulcre","year":"2016","journal-title":"J Neurosci"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0405","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3233\/JAD-2012-120712","article-title":"A highly selective and specific PET tracer for imaging of tau pathologies","volume":"31","author":"Zhang","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0410","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0415","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00401-006-0127-z","article-title":"Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry","volume":"112","author":"Braak","year":"2006","journal-title":"Acta Neuropathol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0420","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrn3887","article-title":"Spreading of pathology in neurodegenerative diseases: a focus on human studies","volume":"16","author":"Brettschneider","year":"2015","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0425","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.nicl.2017.09.016","article-title":"Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease","volume":"17","author":"Iaccarino","year":"2018","journal-title":"Neuroimage Clin"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0430","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/nn.4018","article-title":"Three dimensions of the amyloid hypothesis: time, space and \u2018wingmen\u2019","volume":"18","author":"Musiek","year":"2015","journal-title":"Nat Neurosci"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0435","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","article-title":"PET imaging of tau deposition in the aging human brain","volume":"89","author":"Scholl","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0440","first-page":"21","article-title":"Tau-PET uptake: regional variation in average SUVR and impact of amyloid deposition","volume":"6","author":"Vemuri","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0445","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0450","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.arr.2017.03.002","article-title":"In vivo tau PET imaging in dementia: pathophysiology, radiotracer quantification, and a systematic review of clinical findings","volume":"36","author":"Hall","year":"2017","journal-title":"Ageing Res Rev"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0455","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/jama.2018.12917","article-title":"Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders","volume":"320","author":"Ossenkoppele","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0460","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40336-018-0290-y","article-title":"The development and validation of tau PET tracers: current status and future directions","volume":"6","author":"Okamura","year":"2018","journal-title":"Clin Transl Imaging"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0465","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/NEN.0b013e31824b211b","article-title":"Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005\u20132010","volume":"71","author":"Beach","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0470","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.trci.2017.06.001","article-title":"Determining the impact of psychosis on rates of false-positive and false-negative diagnosis in Alzheimer's disease","volume":"3","author":"Fischer","year":"2017","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0475","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1001\/jama.2015.4669","article-title":"Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis","volume":"313","author":"Ossenkoppele","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0480","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1093\/brain\/aww159","article-title":"Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease","volume":"139","author":"Chetelat","year":"2016","journal-title":"Brain"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0485","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1212\/WNL.0000000000002576","article-title":"Alzheimer's disease neuroimaging I. Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI","volume":"86","author":"Landau","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0490","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/1471-2318-13-137","article-title":"Characteristics of patients misdiagnosed with Alzheimer's disease and their medication use: an analysis of the NACC-UDS database","volume":"13","author":"Gaugler","year":"2013","journal-title":"BMC Geriatr"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0495","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.jalz.2015.06.1889","article-title":"Medical costs of Alzheimer's disease misdiagnosis among US Medicare beneficiaries","volume":"11","author":"Hunter","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0500","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1053\/j.semnuclmed.2016.09.006","article-title":"Abeta-amyloid and tau imaging in dementia","volume":"47","author":"Villemagne","year":"2017","journal-title":"Semin Nucl Med"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2013.01.002","article-title":"Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association","volume":"9","author":"Johnson","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0510","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.2967\/jnumed.116.185017","article-title":"Clinical use and utility of amyloid imaging","volume":"58","author":"Barthel","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0515","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3233\/JAD-171093","article-title":"A systematic review and aggregated analysis on the impact of amyloid PET brain imaging on the diagnosis, diagnostic confidence, and management of patients being evaluated for Alzheimer's disease","volume":"63","author":"Fantoni","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0520","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.3233\/JAD-180646","article-title":"The incremental diagnostic value of [18F]Florbetaben PET and the pivotal role of the neuropsychological assessment in clinical practice","volume":"67","author":"Spallazzi","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0525","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/jama.2019.2000","article-title":"Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia","volume":"321","author":"Rabinovici","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0530","first-page":"339","article-title":"Alzheimer disease pharmacologic treatment and treatment research","volume":"19","author":"Schneider","year":"2013","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0535","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/01.JGP.0000231744.69631.33","article-title":"Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia","volume":"15","author":"Mendez","year":"2007","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0540","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1474-4422(12)70320-4","article-title":"Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"12","author":"Boxer","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0545","author":"(CMS) CfMMS"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0550","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3233\/JAD-150778","article-title":"A meta-analysis of Alzheimer's disease incidence and prevalence comparing African-Americans and Caucasians","volume":"50","author":"Steenland","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0555","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.nicl.2017.09.014","article-title":"Beta-amyloid and cortical thickness reveal racial disparities in preclinical Alzheimer's disease","volume":"16","author":"McDonough","year":"2017","journal-title":"Neuroimage Clin"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0560","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1212\/WNL.0000000000001834","article-title":"Mixed pathology is more likely in black than white decedents with Alzheimer dementia","volume":"85","author":"Barnes","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0565","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jalz.2016.03.004","article-title":"Neuropathologic differences by race from the National Alzheimer's Coordinating Center","volume":"12","author":"Graff-Radford","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0575","first-page":"413","article-title":"Amyloid positron emission tomography candidates may focus more on benefits than risks of results disclosure","volume":"10","author":"Lingler","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0580","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13195-017-0321-3","article-title":"Amnestic MCI patients' experiences after disclosure of their amyloid PET result in a research context","volume":"9","author":"Vanderschaeghe","year":"2017","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0585","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1212\/01.wnl.0000326146.60732.d6","article-title":"Imaging amyloid deposition in Lewy body diseases","volume":"71","author":"Gomperts","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0590","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.nicl.2017.05.002","article-title":"Amyloid positron emission tomography in sporadic cerebral amyloid angiopathy: a systematic critical update","volume":"15","author":"Farid","year":"2017","journal-title":"Neuroimage Clin"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0595","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0600","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0605","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer's disease","volume":"378","author":"Honig","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0610","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","article-title":"Randomized trial of verubecestat for prodromal Alzheimer's disease","volume":"380","author":"Egan","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0615","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces Abeta plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0620","author":"Biogen"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0625","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1212\/WNL.0000000000001877","article-title":"Amyloid-beta 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials","volume":"85","author":"Liu","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0630","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","article-title":"Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study","volume":"12","author":"Villemagne","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0635","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer's disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0640","doi-asserted-by":"crossref","first-page":"e1295","DOI":"10.1212\/WNL.0000000000006277","article-title":"Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease","volume":"91","author":"McDade","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0645","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1001\/archneurol.2011.666","article-title":"Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals","volume":"69","author":"Perrotin","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0650","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1212\/WNL.0b013e31828ab35d","article-title":"Meta-analysis of amyloid-cognition relations in cognitively normal older adults","volume":"80","author":"Hedden","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0655","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1001\/jamapsychiatry.2017.3391","article-title":"Association of cerebral amyloid-beta aggregation with cognitive functioning in persons without dementia","volume":"75","author":"Jansen","year":"2018","journal-title":"JAMA Psychiat"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0660","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1474-4422(13)70194-7","article-title":"Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study","volume":"12","author":"Vos","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2012.10.012","article-title":"The effect of amyloid beta on cognitive decline is modulated by neural integrity in cognitively normal elderly","volume":"9","author":"Wirth","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0670","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jamaneurol.2017.0892","article-title":"Association of longitudinal cognitive decline with amyloid burden in middle-aged and older adults: evidence for a dose-response relationship","volume":"74","author":"Farrell","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0675","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.jalz.2017.01.018","article-title":"Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid beta","volume":"13","author":"Mormino","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0680","doi-asserted-by":"crossref","first-page":"e1567","DOI":"10.1212\/WNL.0000000000007248","article-title":"ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes","volume":"92","author":"Soldan","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0685","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1212\/WNL.0000000000004627","article-title":"Subjective cognitive decline and beta-amyloid burden predict cognitive change in healthy elderly","volume":"89","author":"Vogel","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0690","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1001\/jama.2017.6669","article-title":"Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons","volume":"317","author":"Donohue","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0695","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S1474-4422(16)30125-9","article-title":"Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study","volume":"15","author":"Burnham","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0700","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/jamaneurol.2014.2031","article-title":"Synergistic effect of beta-amyloid and neurodegeneration on cognitive decline in clinically normal individuals","volume":"71","author":"Mormino","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0705","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jamaneurol.2016.0194","article-title":"Hypothetical preclinical Alzheimer disease groups and longitudinal cognitive change","volume":"73","author":"Soldan","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0710","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1093\/brain\/awy150","article-title":"Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults","volume":"141","author":"Bilgel","year":"2018","journal-title":"Brain"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0715","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/brain\/awz025","article-title":"Entorhinal cortex tau, amyloid-beta, cortical thickness and memory performance in non-demented subjects","volume":"142","author":"Knopman","year":"2019","journal-title":"Brain"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0720","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/ana.22333","article-title":"Amyloid-beta associated cortical thinning in clinically normal elderly","volume":"69","author":"Becker","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0725","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jamaneurol.2013.1062","article-title":"Cross-sectional and longitudinal analysis of the relationship between Abeta deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease","volume":"70","author":"Dore","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0730","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1212\/WNL.0000000000001375","article-title":"Brain structure and function as mediators of the effects of amyloid on memory","volume":"84","author":"Mattsson","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0735","doi-asserted-by":"crossref","first-page":"5553","DOI":"10.1523\/JNEUROSCI.4409-12.2013","article-title":"Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not beta-amyloid in cognitively normal older individuals","volume":"33","author":"Wirth","year":"2013","journal-title":"J Neurosci"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0740","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.neurobiolaging.2015.10.013","article-title":"Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis","volume":"39","author":"Andrews","year":"2016","journal-title":"Neurobiol Aging"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0745","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1212\/WNL.0b013e3181c918b5","article-title":"Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia","volume":"74","author":"Bourgeat","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0750","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1212\/WNL.0b013e318246d67a","article-title":"Accelerated cortical atrophy in cognitively normal elderly with high beta-amyloid deposition","volume":"78","author":"Chetelat","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0755","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1001\/jamaneurol.2016.2642","article-title":"Longitudinal beta-amyloid deposition and hippocampal volume in preclinical Alzheimer disease and suspected non-Alzheimer disease pathophysiology","volume":"73","author":"Gordon","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0760","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jalz.2018.04.011","article-title":"PET staging of amyloidosis using striatum","volume":"14","author":"Hanseeuw","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0765","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamaneurol.2013.182","article-title":"Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with beta-amyloidosis","volume":"70","author":"Knopman","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0770","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/hbm.22173","article-title":"Covarying alterations in Abeta deposition, glucose metabolism, and gray matter volume in cognitively normal elderly","volume":"35","author":"Oh","year":"2014","journal-title":"Hum Brain Mapp"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0775","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1093\/brain\/aws113","article-title":"Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement","volume":"135","author":"Ossenkoppele","year":"2012","journal-title":"Brain"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0780","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.neurobiolaging.2013.09.028","article-title":"Amyloid burden and neural function in people at risk for Alzheimer's disease","volume":"35","author":"Johnson","year":"2014","journal-title":"Neurobiol Aging"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0785","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/brain\/aww108","article-title":"Dynamic relationships between age, amyloid-beta deposition, and glucose metabolism link to the regional vulnerability to Alzheimer's disease","volume":"139","author":"Oh","year":"2016","journal-title":"Brain"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0790","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1212\/WNL.0000000000000467","article-title":"Association of hypometabolism and amyloid levels in aging, normal subjects","volume":"82","author":"Lowe","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0795","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/mp.2016.37","article-title":"Amyloid-beta and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease","volume":"22","author":"Pascoal","year":"2017","journal-title":"Mol Psychiatry"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0800","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1093\/cercor\/bhy078","article-title":"Relationships between tau and glucose metabolism reflect Alzheimer's disease pathology in cognitively normal older adults","volume":"29","author":"Adams","year":"2019","journal-title":"Cereb Cortex"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0805","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.neuron.2005.10.028","article-title":"Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo","volume":"48","author":"Cirrito","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0810","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nn.2801","article-title":"Neuronal activity regulates the regional vulnerability to amyloid-beta deposition","volume":"14","author":"Bero","year":"2011","journal-title":"Nat Neurosci"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0815","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/jamaneurol.2016.6091","article-title":"Association between childhood-onset epilepsy and amyloid burden 5 decades later","volume":"74","author":"Joutsa","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0820","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.tics.2011.09.004","article-title":"Lifespan brain activity, beta-amyloid, and Alzheimer's disease","volume":"15","author":"Jagust","year":"2011","journal-title":"Trends Cogn Sci"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0825","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1093\/cercor\/bhr025","article-title":"Relationships between beta-amyloid and functional connectivity in different components of the default mode network in aging","volume":"21","author":"Mormino","year":"2011","journal-title":"Cereb Cortex"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0830","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1093\/cercor\/bhz020","article-title":"Association between earliest amyloid uptake and functional connectivity in cognitively unimpaired elderly","volume":"29","author":"Hahn","year":"2019","journal-title":"Cereb Cortex"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0835","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/cercor\/bhr255","article-title":"Abeta deposition in aging is associated with increases in brain activation during successful memory encoding","volume":"22","author":"Mormino","year":"2012","journal-title":"Cereb Cortex"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0840","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.22978","article-title":"Hippocampal activation is associated with longitudinal amyloid accumulation and cognitive decline","volume":"6","author":"Leal","year":"2017","journal-title":"Elife"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0845","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuron.2009.07.003","article-title":"Amyloid deposition is associated with impaired default network function in older persons without dementia","volume":"63","author":"Sperling","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0850","doi-asserted-by":"crossref","first-page":"12686","DOI":"10.1523\/JNEUROSCI.3189-09.2009","article-title":"Disruption of functional connectivity in clinically normal older adults harboring amyloid burden","volume":"29","author":"Hedden","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0855","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.biopsych.2009.08.024","article-title":"Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly","volume":"67","author":"Sheline","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0860","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.neuroimage.2017.07.050","article-title":"AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: defining a summary measure","volume":"161","author":"Mishra","year":"2017","journal-title":"Neuroimage"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0865","doi-asserted-by":"crossref","first-page":"P222","DOI":"10.1016\/j.jalz.2018.06.2347","article-title":"Early increase in tau-PET signal is associated with A\u03b2 burden, CSF P-tau levels and cognition in cognitively normal late-middle-aged adults","volume":"14","author":"McSweeney","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0870","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/NEN.0b013e318232a379","article-title":"Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years","volume":"70","author":"Braak","year":"2011","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0875","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00401-018-1855-6","article-title":"Tau seeding activity begins in the transentorhinal\/entorhinal regions and anticipates phospho-tau pathology in Alzheimer's disease and PART","volume":"136","author":"Kaufman","year":"2018","journal-title":"Acta Neuropathol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0880","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1212\/WNL.0000000000000386","article-title":"Rates of beta-amyloid accumulation are independent of hippocampal neurodegeneration","volume":"82","author":"Jack","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0885","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1474-4422(15)00323-3","article-title":"Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study","volume":"15","author":"Jack","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0890","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awz090","article-title":"A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia","author":"Pontecorvo","year":"2019","journal-title":"Brain"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0895","first-page":"358","article-title":"Clinical use of amyloid-positron emission tomography neuroimaging: practical and bioethical considerations","volume":"1","author":"Witte","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0900","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jalz.2009.04.1229","article-title":"Early dementia diagnosis and the risk of suicide and euthanasia","volume":"6","author":"Draper","year":"2010","journal-title":"Alzheimers Dement"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0905","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamaneurol.2017.2954","article-title":"Comprehension of an elevated amyloid positron emission tomography biomarker result by cognitively normal older adults","volume":"75","author":"Mozersky","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0910","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13195-015-0112-7","article-title":"Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants","volume":"7","author":"Harkins","year":"2015","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0915","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jalz.2017.01.022","article-title":"Safety of disclosing amyloid status in cognitively normal older adults","volume":"13","author":"Burns","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0920","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.neuron.2011.01.002","article-title":"Anti-abeta therapeutics in Alzheimer's disease: the need for a paradigm shift","volume":"69","author":"Golde","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0925","doi-asserted-by":"crossref","first-page":"111cm133","DOI":"10.1126\/scitranslmed.3002609","article-title":"Testing the right target and right drug at the right stage","volume":"3","author":"Sperling","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0930","doi-asserted-by":"crossref","first-page":"228fs213","DOI":"10.1126\/scitranslmed.3007941","article-title":"The A4 study: stopping AD before symptoms begin?","volume":"6","author":"Sperling","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0935","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jalz.2016.07.005","article-title":"The DIAN-TU next generation Alzheimer's prevention trial: adaptive design and disease progression model","volume":"13","author":"Bateman","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0940","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.neuroimage.2011.07.098","article-title":"Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant","volume":"59","author":"Mormino","year":"2012","journal-title":"Neuroimage"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0945","doi-asserted-by":"crossref","first-page":"e1452","DOI":"10.1212\/WNL.0000000000005354","article-title":"Alzheimer's disease neuroimaging I. Memory decline accompanies subthreshold amyloid accumulation","volume":"90","author":"Landau","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0950","doi-asserted-by":"crossref","first-page":"e1809","DOI":"10.1212\/WNL.0000000000006469","article-title":"Regional amyloid accumulation and cognitive decline in initially amyloid-negative adults","volume":"91","author":"Farrell","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0955","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1523\/JNEUROSCI.0485-18.2018","article-title":"Subthreshold amyloid predicts tau deposition in aging","volume":"38","author":"Leal","year":"2018","journal-title":"J Neurosci"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0960","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0197-4580(97)00056-0","article-title":"Frequency of stages of Alzheimer-related lesions in different age categories","volume":"18","author":"Braak","year":"1997","journal-title":"Neurobiol Aging"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0965","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","article-title":"Phases of A beta-deposition in the human brain and its relevance for the development of AD","volume":"58","author":"Thal","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0970","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/ana.24711","article-title":"In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum","volume":"80","author":"Cho","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0975","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1212\/WNL.0000000000004643","article-title":"In vivo staging of regional amyloid deposition","volume":"89","author":"Grothe","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0980","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1093\/brain\/awt146","article-title":"In vivo characterization of the early states of the amyloid-beta network","volume":"136","author":"Sepulcre","year":"2013","journal-title":"Brain"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0985","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1212\/WNL.0b013e318245d295","article-title":"Beta-amyloid burden in healthy aging: regional distribution and cognitive consequences","volume":"78","author":"Rodrigue","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0990","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1212\/WNL.0000000000003425","article-title":"Amyloid deposition in younger adults is linked to episodic memory performance","volume":"87","author":"Bischof","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb0995","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neurobiolaging.2018.10.011","article-title":"Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the dominantly inherited Alzheimer network","volume":"75","author":"Bussy","year":"2019","journal-title":"Neurobiol Aging"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1000","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/WNN.0000000000000071","article-title":"Alzheimer lesions in the autopsied brains of people 30 to 50 years of age","volume":"28","author":"Pletnikova","year":"2015","journal-title":"Cogn Behav Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1005","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neurobiolaging.2018.07.007","article-title":"The spectrum of preclinical Alzheimer's disease pathology and its modulation by ApoE genotype","volume":"71","author":"Pletnikova","year":"2018","journal-title":"Neurobiol Aging"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1010","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","article-title":"Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis","volume":"313","author":"Jansen","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1015","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1017\/S0033291700003081","article-title":"Familial Alzheimer Dementia: a prevalent disorder with specific clinical features","volume":"14","author":"Breitner","year":"1984","journal-title":"Psychol Med"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1020","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/archpsyc.1987.01800170019003","article-title":"Alzheimer's disease. Morbid risk among first-degree relatives approximates 50% by 90 years of age","volume":"44","author":"Mohs","year":"1987","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1025","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/ana.410330306","article-title":"Risk factors for late-onset Alzheimer's disease: a population-based, case-control study","volume":"33","author":"Fratiglioni","year":"1993","journal-title":"Ann Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1030","doi-asserted-by":"crossref","first-page":"e1745","DOI":"10.1212\/WNL.0000000000007231","article-title":"Relative risk for Alzheimer disease based on complete family history","volume":"92","author":"Cannon-Albright","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1035","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.neurobiolaging.2012.03.002","article-title":"Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents","volume":"34","author":"Mosconi","year":"2013","journal-title":"Neurobiol Aging"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1040","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1212\/WNL.0000000000000181","article-title":"Brain imaging of cognitively normal individuals with 2 parents affected by late-onset AD","volume":"82","author":"Mosconi","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1045","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1001\/jamaneurol.2017.5135","article-title":"Proximity to parental symptom onset and amyloid-beta burden in sporadic Alzheimer disease","volume":"75","author":"Villeneuve","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1050","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/0891988705281882","article-title":"Middle-aged children of persons with Alzheimer's disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer's Prevention","volume":"18","author":"Sager","year":"2005","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1055","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/ajmg.b.32399","article-title":"Influence of family history of dementia in the development and progression of late-onset Alzheimer's disease","volume":"171B","author":"Scarabino","year":"2016","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1060","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13195-018-0411-x","article-title":"Synergistic interaction between APOE and family history of Alzheimer's disease on cerebral amyloid deposition and glucose metabolism","volume":"10","author":"Yi","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1065","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/0140-6736(93)91705-Q","article-title":"Apolipoprotein E polymorphism and Alzheimer's disease","volume":"342","author":"Poirier","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1070","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S1474-4422(18)30053-X","article-title":"The effect of APOE and other common genetic variants on the onset of Alzheimer's disease and dementia: a community-based cohort study","volume":"17","author":"van der Lee","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1075","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nrn3114","article-title":"Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders","volume":"12","author":"Zlokovic","year":"2011","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1080","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3389\/fnagi.2014.00154","article-title":"The potential applications of Apolipoprotein E in personalized medicine","volume":"6","author":"Villeneuve","year":"2014","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1085","first-page":"236","article-title":"Rationale and structure for a new center for studies on prevention of Alzheimer's disease (StoP-AD)","volume":"3","author":"Breitner","year":"2016","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1090","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/S0140-6736(17)31363-6","article-title":"Dementia prevention, intervention, and care","volume":"390","author":"Livingston","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1095","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/archneur.62.10.1556","article-title":"Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease","volume":"62","author":"Kivipelto","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1100","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1212\/01.WNL.0000149519.47454.F2","article-title":"Midlife cardiovascular risk factors and risk of dementia in late life","volume":"64","author":"Whitmer","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1105","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/ana.25246","article-title":"Combined neuropathological pathways account for age-related risk of dementia","volume":"84","author":"Power","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1110","doi-asserted-by":"crossref","first-page":"11934","DOI":"10.1038\/ncomms11934","article-title":"Alzheimer's disease neuroimaging I. Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis","volume":"7","author":"Iturria-Medina","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1115","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/jama.2018.21442","article-title":"Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial","volume":"321","author":"SPRINT MIND Investigators for the SPRINT Research Group","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1120","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/jamaneurol.2017.0244","article-title":"Evaluation of amyloid protective factors and Alzheimer disease neurodegeneration protective factors in elderly individuals","volume":"74","author":"Vemuri","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1125","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/jama.2017.3090","article-title":"Association between midlife vascular risk factors and estimated brain amyloid deposition","volume":"317","author":"Gottesman","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1130","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1212\/WNL.0000000000004749","article-title":"Increased midlife triglycerides predict brain beta-amyloid and tau pathology 20 years later","volume":"90","author":"Nagga","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1135","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamaneurol.2018.1123","article-title":"Interactive associations of vascular risk and beta-amyloid burden with cognitive decline in clinically normal elderly individuals: findings from the harvard aging brain study","volume":"75","author":"Rabin","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1140","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1001\/jamaneurol.2013.1342","article-title":"Risk factors for beta-amyloid deposition in healthy aging: vascular and genetic effects","volume":"70","author":"Rodrigue","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1145","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamaneurol.2013.5390","article-title":"Associations between serum cholesterol levels and cerebral amyloidosis","volume":"71","author":"Reed","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1150","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.jalz.2018.06.3059","article-title":"Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease","volume":"14","author":"Muller","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1155","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3389\/fnagi.2015.00134","article-title":"Cognitive reserve and lifestyle: moving towards preclinical Alzheimer's disease","volume":"7","author":"Arenaza-Urquijo","year":"2015","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1160","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1001\/archneurol.2011.2748","article-title":"Association of lifetime cognitive engagement and low beta-amyloid deposition","volume":"69","author":"Landau","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1165","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/ana.22096","article-title":"Exercise and Alzheimer's disease biomarkers in cognitively normal older adults","volume":"68","author":"Liang","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1170","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/j.neurobiolaging.2014.02.015","article-title":"Neuroprotective pathways: lifestyle activity, brain pathology, and cognition in cognitively normal older adults","volume":"35","author":"Wirth","year":"2014","journal-title":"Neurobiol Aging"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1175","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neurobiolaging.2017.06.016","article-title":"Association between educational attainment and amyloid deposition across the spectrum from normal cognition to dementia: neuroimaging evidence for protection and compensation","volume":"59","author":"Arenaza-Urquijo","year":"2017","journal-title":"Neurobiol Aging"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1180","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4236\/ami.2014.44006","article-title":"Physical activity, mediterranean diet and biomarkers-assessed risk of Alzheimer's: a multi-modality brain imaging study","volume":"4","author":"Matthews","year":"2014","journal-title":"Adv J Mol Imaging"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb9010","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.jagp.2018.03.018","article-title":"The relationship of current cognitive activity to brain amyloid burden and glucose metabolism","volume":"26","author":"Lyons","year":"2018","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1185","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/mp.2012.107","article-title":"Physical activity and amyloid-beta plasma and brain levels: results from the Australian imaging, biomarkers and lifestyle study of ageing","volume":"18","author":"Brown","year":"2013","journal-title":"Mol Psychiatry"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1190","doi-asserted-by":"crossref","first-page":"8612","DOI":"10.1523\/JNEUROSCI.4612-13.2014","article-title":"Gene-environment interactions: lifetime cognitive activity, APOE genotype, and beta-amyloid burden","volume":"34","author":"Wirth","year":"2014","journal-title":"J Neurosci"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1195","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1212\/WNL.0000000000002490","article-title":"Effect of intellectual enrichment on AD biomarker trajectories: longitudinal imaging study","volume":"86","author":"Vemuri","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1200","first-page":"1537","article-title":"Self-reported sleep and beta-amyloid deposition in community-dwelling older adults","volume":"70","author":"Spira","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1205","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsy184","article-title":"Excessive daytime sleepiness and napping in cognitively normal adults: associations with subsequent amyloid deposition measured by PiB PET","volume":"41","author":"Spira","year":"2018","journal-title":"Sleep"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1210","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.neurobiolaging.2016.02.009","article-title":"Relationships between sleep quality and brain volume, metabolism, and amyloid deposition in late adulthood","volume":"41","author":"Branger","year":"2016","journal-title":"Neurobiol Aging"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1215","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1073\/pnas.1721694115","article-title":"Beta-amyloid accumulation in the human brain after one night of sleep deprivation","volume":"115","author":"Shokri-Kojori","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1220","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1212\/WNL.0000000000002167","article-title":"Amyloid burden and sleep blood pressure in amnestic mild cognitive impairment","volume":"85","author":"Tarumi","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1225","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsz048","article-title":"Obstructive sleep apnea and longitudinal Alzheimer's disease biomarker changes","author":"Bubu","year":"2019","journal-title":"Sleep"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1230","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.1241224","article-title":"Sleep drives metabolite clearance from the adult brain","volume":"342","author":"Xie","year":"2013","journal-title":"Science"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1235","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jamaneurol.2018.0049","article-title":"Association of excessive daytime sleepiness with longitudinal beta-amyloid accumulation in elderly persons without dementia","volume":"75","author":"Carvalho","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1240","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/nn.4035","article-title":"Beta-amyloid disrupts human NREM slow waves and related hippocampus-dependent memory consolidation","volume":"18","author":"Mander","year":"2015","journal-title":"Nat Neurosci"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1245","first-page":"142","article-title":"Brain and cognitive correlates of sleep fragmentation in elderly subjects with and without cognitive deficits","volume":"11","author":"Andre","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1250","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/ana.25373","article-title":"Reduced brain amyloid burden in elderly patients with narcolepsy type 1","volume":"85","author":"Gabelle","year":"2019","journal-title":"Ann Neurol"},{"issue":"suppl","key":"10.1016\/bs.pmbts.2019.05.001_bb1255","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1097\/WAD.0b013e3181f14a14","article-title":"Barriers and facilitators of African American participation in Alzheimer disease biomarker research","volume":"24","author":"Williams","year":"2010","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1260","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1001\/jamaneurol.2018.3444","article-title":"Biomarkers for Alzheimer dementia in diverse racial and ethnic minorities\u2014a public health priority","volume":"76","author":"Barnes","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/bs.pmbts.2019.05.001_bb1265","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1474-4422(11)70072-2","article-title":"The projected effect of risk factor reduction on Alzheimer's disease prevalence","volume":"10","author":"Barnes","year":"2011","journal-title":"Lancet Neurol"}],"container-title":["Progress in Molecular Biology and Translational Science","Brain Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117319300791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117319300791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T07:27:59Z","timestamp":1721374079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877117319300791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9780128183618"],"references-count":253,"URL":"https:\/\/doi.org\/10.1016\/bs.pmbts.2019.05.001","relation":{},"ISSN":["1877-1173"],"issn-type":[{"value":"1877-1173","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}